pharmaceutical investing AbbVie Presents New Phase 3 AFFIRM Data Showing Clinical and Endoscopic Outcomes With Subcutaneous SKYRIZI® in Patients With Moderately to Severely Active Crohn's Disease
pharmaceutical investing New SKYRIZI® and RINVOQ® Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease
pharmaceutical investing AbbVie's Telisotuzumab Adizutecan Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLC
pharmaceutical investing AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
pharmaceutical investing Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
pharmaceutical investing AbbVie Presents Long-Term RINVOQ® Data Showing Continued Repigmentation in Non-Segmental Vitiligo
pharmaceutical investing AbbVie Presents Detailed Phase 1 Data for ABBV-295, a Long-Acting Amylin Analog, Demonstrating Favorable Tolerability and Pharmacokinetic Profile at EASD 2026
pharmaceutical investing AbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at EADV 2026
pharmaceutical investing AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress
pharmaceutical investing AbbVie Partners with Valkai to Apply Advanced AI Across Targeted Areas of Clinical Development
pharmaceutical investing EPKINLY® receives Health Canada Approval for Adults with Follicular Lymphoma
pharmaceutical investing Allergan Aesthetics Debuts AA Signature in the United States with SKIN360, Its First Multimodal Consultation Approach
pharmaceutical investing AbbVie Announces European Commission Approval of RINVOQ® for the Treatment of Children with Active Polyarticular Juvenile Idiopathic Arthritis
Angkor Resources Reports University Study Supporting Copper-Molybdenum Porphyry Potential at Andong Bor, Cambodia
VanadiumCorp and Université de Sherbrooke Announce Publication of Peer-Reviewed Research on Lac Doré Vanadiferous Titanomagnetite
